Pyridinedicarboxylic acid derivatives and pharmaceutical compositions

US4963571A · kind A · utility

Assignee

• Glaxo SpA · IT

Inventors

• Claudio Semeraro · Bresso, IT
• Dino Micheli · Carpi, IT
• Daniele Pieraccioli · Verona, IT
• Giovanni Gaviraghi · Verona, IT
• Alan David Borthwick · London, GB

Key dates

• Filing date: Nov 16, 1988
• Grant date: Oct 16, 1990
• Expiry date: Nov 16, 2008

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds are described of the formula ##STR1## wherein R.sub.1 and R.sub.4 independently represent a C.sub.1-4 alkyl group; PA1 R.sub.2 and R.sub.3 independently represent a C.sub.1-6 straight or branched alkyl chain or alkoxy group; PA1 R.sub.5 represents a straight or branched chain C.sub.1-13 alkyl group or a C.sub.5-8 cycloalkyl group which may be substituted by a C.sub.1-3 alkyl substituent; PA1 R.sub.6 represents a halogen atom or a straight or branched C.sub.1-3 alkyl group. PA1 R.sub.7 represents a C.sub.1-4 alkyl group [optionally substituted by hydroxy, C.sub.1-3 alkoxy or trifluoromethyl or by a group NR.sub.8 R.sub.9 where NR.sub.8 R.sub.9 forms a saturated 5 to 7 membered ring optionally containing an additional heleroatom which is oxygen]; or R.sub.7 represents a phenylC.sub.1-2 alkyl group in which the portion is optionally substituted by 1 to 3 C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups or halogen atoms. The compounds representd by formula (I) reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as hypertension.